Getting personal with rare disease patients. By Nancy Pilcher, RN November 28, 2016 Complex. It’s the word most often associated with the orphan drug market. Commercialization success …
[[eBook]] Life-changing LAUNCH
Manufacturer perspectives on maximizing success for orphan drug commercialization You’re a manufacturer of orphan drugs, which means the new product you’ve spent years developing has …
Chris Garabedian – Orphan Drug Congress Interview Part 1
Andre Singer (Project Director- World Orphan Drug Congress USA) and Chris Garabedian(Former CEO of Sarepta Therapeutics) discuss the current state of affairs in the Orphan …
[[WHITEPAPER]] Global Rare Disease Drug Development: Understanding and mitigating its complexities
This insight brief examines the varied definitions and regulatory pathways for rare disease therapies. The authors describe QuintilesIMS’s proven patient centric approaches to study planning, …
What’s the outlook for the Orphan drug market in 2022?
By Lisa Urquhart, EP Vantage Editor and Report Contributor Annual “EvaluatePharma® Orphan Drug 2017 Report” sees continued growth for orphan drugs, approximately double overall prescription …
Towards a New Way of Evaluating Orphan Drugs at CADTH
McKesson Canada is the leading provider of market access services connecting patients to orphan drugs and other drug therapies within the Canadian health care market. …
[Whitepaper] It is never too early to think “drug product”
Drug product will follow you all the way through the clinical trials and into the commercial supply to healthcare systems and the patients. Download the whitepaper …
Positive Collaboration – Alström Syndrome UK
Kerry Leeson-Beevers, National Development Manager at Alström Syndrome UK joined us at World Orphan Drug Congress Europe 2015 to provide insight into the role how positive collaboration …